Chloroform

Chloroform

SCHEMBL1367016

ClC(Cl)Cl.O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.O=C(C=Cc1ccccc1)C=Cc1ccccc1.[Pd]

nearest known ligand 0.79

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.79
CYP2C9 P11712 3/20 0.79
MAPT P10636 3/20 0.79
PLIN1 O60240 2/20 0.79
LMNA P02545 2/20 0.79
RECQL P46063 2/20 0.79
PLIN5 Q00G26 2/20 0.79
ABHD5 Q8WTS1 2/20 0.79
CYP2D6 P10635 2/20 0.79
F3 P13726 2/20 0.79
ALDH1A1 P00352 2/20 0.79
SMN1; SMN2 Q16637 1/20 0.79
HDAC3 O15379 2/20 0.59
HDAC4 P56524 2/20 0.59
HDAC1 Q13547 2/20 0.59
HDAC2 Q92769 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
TNKS O95271 1/20 0.59
HCAR2 Q8TDS4 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chloroform SCHEMBL2128854 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL1827856 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL7629150 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL2128849 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL84057 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL2832028 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL18788602 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL28370740 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL29371090 1.00 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL1043119 0.98 CYP1A2 (0.83) CYP1A2CYP2C9MAPTPLIN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10000486-B2 Antiviral drugs for treatment of arenavirus infection KINETA VIRAL HEMORRHAGIC FEVER, LLC (US) 2018-06-19 US disclosed
EP-2814486-B1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION KINETA FOUR LLC (US) 2018-04-11 EP disclosed
US-20170137422-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION Kineta Four, LLC (US) 2017-05-18 US disclosed
US-9498470-B2 Antiviral drugs for treatment of arenavirus infection Kineta Four, LLC (US) 2016-11-22 US disclosed
US-20150023916-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION SIGA TECHNOLOGIES INC. (US) 2015-01-22 US disclosed
US-8673891-B2 Aminopyrazine derivative and medicine NIPPON SHINYAKU CO., LTD. (JP) 2014-03-18 US disclosed
EP-2394999-B1 AMINOPYRAZINE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO LTD (JP) 2014-01-29 EP disclosed
US-8586591-B2 Aminopyrazine derivative and medicine NIPPON SHINYAKU CO., LTD. (JP) 2013-11-19 US disclosed
EP-2394999-A1 AMINOPYRAZINE DERIVATIVE AND MEDICINE Nippon Shinyaku Co., Ltd. (JP) 2011-12-14 EP disclosed
US-20110288065-A1 AMINOPYRAZINE DERIVATIVE AND MEDICINE NIPPON SHINYAKU CO., LTD. (JP) 2011-11-24 US disclosed
US-6982257-B1 Vitamin D3 derivative and its production method TEIJIN LIMITED (JP) 2006-01-03 US disclosed
EP-0957088-B1 VITAMIN D3 DERIVATIVES AND PROCESS FOR PRODUCING THE SAME TEIJIN LTD (JP) 2002-12-18 EP disclosed
EP-0957088-A1 VITAMIN D3 DERIVATIVES AND PROCESS FOR PRODUCING THE SAME TEIJIN LIMITED (JP) 1999-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10000486-B2 Antiviral drugs for treatment of arenavirus infection EIF2AK2, ZC3HAV1, SARS1 CYP1A2 4179/4885CYP2C9 3296/4885MAPT 4118/4885
US-20150023916-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION EIF2AK2, ZC3HAV1, SARS1 CYP1A2 4179/4885CYP2C9 3296/4885MAPT 4118/4885
US-20170137422-A1 ANTIVIRAL DRUGS FOR TREATMENT OF ARENAVIRUS INFECTION EIF2AK2, ZC3HAV1, SARS1 CYP1A2 4179/4885CYP2C9 3296/4885MAPT 4118/4885
US-20110288065-A1 AMINOPYRAZINE DERIVATIVE AND MEDICINE MC2R, CNR1, NPY2R CYP1A2 136/4885CYP2C9 397/4885MAPT 4014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.